Adrenocortical carcinoma staging: Difference between revisions

Jump to navigation Jump to search
VisualWikitext
No edit summary
Line 6: Line 6:


==Staging of adrenocortical carcinoma==
==Staging of adrenocortical carcinoma==
The AJCC has designated staging by TNM to define adrenocortical carcinoma<ref name=AJCC Cancer Staging Manual>Adrenal. In: Edge SB, Byrd DR, Compton CC, et al., eds.: AJCC Cancer Staging Manual. 7th ed. New York, NY: Springer, 2010, pp 516-7</ref>
The AJCC has designated staging by TNM to define adrenocortical carcinoma<ref name="AJCC">Adrenal. In: Edge SB, Byrd DR, Compton CC, et al., eds.: AJCC Cancer Staging Manual. 7th ed. New York, NY: Springer, 2010, pp 516-7</ref>
===Staging according to TNM staging system===
===Staging according to TNM staging system===
{|{{table}}
{| {{table}} cellpadding="4" cellspacing="0" style="border:#c9c9c9 1px solid; margin: 1em 1em 1em 0; border-collapse: collapse;"
| Stage
| Stage
| T
| T
Line 35: Line 35:


===Tumor size (T)===
===Tumor size (T)===
{| {{table}}
{| {{table}} cellpadding="4" cellspacing="0" style="border:#c9c9c9 1px solid; margin: 1em 1em 1em 0; border-collapse: collapse;"


| TX
| TX
Line 54: Line 54:
===Lymph nodes (N)===
===Lymph nodes (N)===


{| {{table}}
{| {{table}} cellpadding="4" cellspacing="0" style="border:#c9c9c9 1px solid; margin: 1em 1em 1em 0; border-collapse: collapse;"
| NX
| NX
| Regional lymph nodes cannot be assessed
| Regional lymph nodes cannot be assessed
Line 64: Line 64:


===Metastasis (M)===
===Metastasis (M)===
{| {{table}}
{| {{table}} cellpadding="4" cellspacing="0" style="border:#c9c9c9 1px solid; margin: 1em 1em 1em 0; border-collapse: collapse;"
| M0
| M0
| No distant metastasis
| No distant metastasis
Line 73: Line 73:
==Staging==
==Staging==
<br>
<br>
{| style="border: 0px; font-size: 90%; margin: 3px;" align=center
{| style="border: 0px; font-size: 90%; margin: 3px;" align="center"
|+'''''Thyroid TNM staging'''''
|+'''''Thyroid TNM staging'''''
! style="background: #4479BA; width: 120px;" | {{fontcolor|#FFF|Stage}}
! style="background: #4479BA; width: 120px;" | {{fontcolor|#FFF|Stage}}
Line 85: Line 85:
|-
|-
! style="background: #DCDCDC;" |T1
! style="background: #DCDCDC;" |T1
! style="background: #F5F5F5;" |[[Tumor]] ≤2 cm in greatest dimension limited to the [[thyroid]]
! style="background: #F5F5F5;" |[[Tumor]] ≤5 cm in greatest dimension limited to the [[thyroid|adrenals]]
|-
! style="background: #DCDCDC;" |T1a
! style="background: #F5F5F5;" |[[Tumor]] ≤1 cm, limited to the [[thyroid]]
|-
! style="background: #DCDCDC;" |T1b
! style="background: #F5F5F5;" |[[Tumor]] >1 cm but ≤2 cm in greatest dimension, limited to the [[thyroid]]
|-
|-
! style="background: #DCDCDC;" |T2
! style="background: #DCDCDC;" |T2
! style="background: #F5F5F5;" |[[Tumor]] >2 cm but ≤4 cm in greatest dimension, limited to the [[thyroid]]
! style="background: #F5F5F5;" |[[Tumor]] >5 cm in greatest dimension, limited to the adrenals
|-
|-
! style="background: #DCDCDC;" |T3
! style="background: #DCDCDC;" |T3
! style="background: #F5F5F5;" |[[Tumor]] >4 cm in greatest dimension limited to the [[thyroid]] or any [[tumor]] with minimal extrathyroid extension (e.g., extension to [[sternothyroid muscle]] or perithyroid soft tissues)
! style="background: #F5F5F5;" |[[Tumor]] >4 cm in greatest dimension limited to the [[thyroid]] or any [[tumor]] with minimal extrathyroid extension (e.g., extension to [[sternothyroid muscle]] or perithyroid soft tissues)
|-
|-
! style="background: #DCDCDC;" rowspan=2|T4a
! rowspan="2" style="background: #DCDCDC;" |T4
! style="background: #F5F5F5;" |Moderately advanced [[disease]]
! style="background: #F5F5F5;" |Moderately advanced [[disease]]
|-
|-
! style="background: #F5F5F5;" |[[Tumor]] of any size extending beyond the thyroid capsule to invade subcutaneous [[soft tissue]]s, [[larynx]], [[trachea]], [[esophagus]], or [[recurrent laryngeal nerve]]
! style="background: #F5F5F5;" |[[Tumor]] of any size extending beyond the thyroid capsule to invade subcutaneous [[soft tissue]]s, [[larynx]], [[trachea]], [[esophagus]], or [[recurrent laryngeal nerve]]
|-
! style="background: #DCDCDC;" rowspan=2|T4b
! style="background: #F5F5F5;" |Very advanced [[disease]]
|-
! style="background: #F5F5F5;" |[[Tumor]] invades prevertebral fascia or encases [[carotid artery]] or mediastinal vessel
|}
|}
<br>
<br>
{| style="border: 0px; font-size: 90%; margin: 3px;" align=center
{| style="border: 0px; font-size: 90%; margin: 3px;" align="center"
|+'''''Regional Lymph Nodes (N)'''''
|+'''''Regional Lymph Nodes (N)'''''
! style="background: #4479BA; width: 120px;" | {{fontcolor|#FFF|Stage}}
! style="background: #4479BA; width: 120px;" | {{fontcolor|#FFF|Stage}}
Line 119: Line 108:
|-
|-
! style="background: #DCDCDC;" |N0
! style="background: #DCDCDC;" |N0
! style="background: #F5F5F5;" |No regional lymph node metastasis]]
! style="background: #F5F5F5;" |No regional lymph node metastasis
|-
|-
! style="background: #DCDCDC;" |N1
! style="background: #DCDCDC;" |N1
! style="background: #F5F5F5;" |Regional [[lymph node]] metastasis
! style="background: #F5F5F5;" |Regional [[lymph node]] metastasis
|-
! style="background: #DCDCDC;" |N1a
! style="background: #F5F5F5;" |[[Metastases]] to Level VI (pretracheal, paratracheal, and prelaryngeal/Delphian lymph nodes)
|-
! style="background: #DCDCDC;" |N1b
! style="background: #F5F5F5;" |[[Metastases]] to unilateral, bilateral, or contralateral cervical (Levels I, II, III, IV, or V) or retropharyngeal or superior mediastinal lymph nodes (Level VII)
|}
|}


{| style="border: 0px; font-size: 90%; margin: 3px;" align=center
{| style="border: 0px; font-size: 90%; margin: 3px;" align="center"
|+'''''Distant Metastasis (M)'''''
|+'''''Distant Metastasis (M)'''''
! style="background: #4479BA; width: 120px;" | {{fontcolor|#FFF|Stage}}
! style="background: #4479BA; width: 120px;" | {{fontcolor|#FFF|Stage}}
Line 143: Line 126:
|}
|}


 
{| style="border: 0px; font-size: 90%; margin: 3px;" align="center"
{| style="border: 0px; font-size: 90%; margin: 3px;" align=center
|+'''''Anatomic Stage/Prognostic Groups'''''
|+'''''Anatomic Stage/Prognostic Groups'''''
! style="background: #4479BA; width: 120px;" | {{fontcolor|#FFF|Stage}}
! style="background: #4479BA; width: 120px;" | {{fontcolor|#FFF|Stage}}
Line 151: Line 133:
! style="background: #4479BA; width: 550px;" | {{fontcolor|#FFF|M}}
! style="background: #4479BA; width: 550px;" | {{fontcolor|#FFF|M}}
|-
|-
| style="padding: 5px 5px; background: #DCDCDC;font-weight: bold" colspan=4 align=center| '''Papillary thyroid carcinoma'''
| colspan="4" style="padding: 5px 5px; background: #DCDCDC;font-weight: bold" align="center" | '''Papillary thyroid carcinoma'''
|-
|-
| style="padding: 5px 5px; background: #DCDCDC;font-weight: bold" colspan=4 | '''YOUNGER THAN 45 YEARS'''
| colspan="4" style="padding: 5px 5px; background: #DCDCDC;font-weight: bold" | '''YOUNGER THAN 45 YEARS'''
|-
|-
! style="background: #DCDCDC;" |I
! style="background: #DCDCDC;" |I
! style="background: #F5F5F5;" |Any T
! style="background: #F5F5F5;" |T1


! style="background: #F5F5F5;" |Any N
! style="background: #F5F5F5;" |N0


! style="background: #F5F5F5;" |M0
! style="background: #F5F5F5;" |M0
|-
|-
! style="background: #DCDCDC;" |II
! style="background: #DCDCDC;" |II
! style="background: #F5F5F5;" |Any T
! style="background: #F5F5F5;" |T2


! style="background: #F5F5F5;" |Any N
! style="background: #F5F5F5;" |N0


! style="background: #F5F5F5;" |M1
|-
| style="padding: 5px 5px; background: #DCDCDC;font-weight: bold" colspan=4 | '''45 YEARS AND OLDER'''
|-
! style="background: #DCDCDC;" |I
! style="background: #F5F5F5;" |T1
! style="background: #F5F5F5;" |Any N
! style="background: #F5F5F5;" |M1
|-
! style="background: #DCDCDC;" |II
! style="background: #F5F5F5;" |T2
! style="background: #F5F5F5;" |N0
! style="background: #F5F5F5;" |M0
! style="background: #F5F5F5;" |M0
|-
|-


! style="background: #DCDCDC;" |III
! style="background: #DCDCDC;" |III
! style="background: #F5F5F5;" |T3
! style="background: #F5F5F5;" |N0
! style="background: #F5F5F5;" |M0
|-
! style="background: #DCDCDC;" |
! style="background: #F5F5F5;" |T1
! style="background: #F5F5F5;" |T1
! style="background: #F5F5F5;" |N1a
! style="background: #F5F5F5;" |N1
! style="background: #F5F5F5;" |M0
! style="background: #F5F5F5;" |M0


Line 199: Line 161:
! style="background: #DCDCDC;" |
! style="background: #DCDCDC;" |
! style="background: #F5F5F5;" |T2
! style="background: #F5F5F5;" |T2
! style="background: #F5F5F5;" |N1a
! style="background: #F5F5F5;" |N1
! style="background: #F5F5F5;" |M0
! style="background: #F5F5F5;" |M0


Line 206: Line 168:
! style="background: #DCDCDC;" |
! style="background: #DCDCDC;" |
! style="background: #F5F5F5;" |T3
! style="background: #F5F5F5;" |T3
! style="background: #F5F5F5;" |N1a
! style="background: #F5F5F5;" |M0
|-
! style="background: #DCDCDC;" |IVA
! style="background: #F5F5F5;" |T4a
! style="background: #F5F5F5;" |N0
! style="background: #F5F5F5;" |N0
! style="background: #F5F5F5;" |M0
! style="background: #F5F5F5;" |M0
Line 218: Line 173:
|-
|-


! style="background: #DCDCDC;" |
! style="background: #DCDCDC;" |IV
! style="background: #F5F5F5;" |T4a
! style="background: #F5F5F5;" |N1a
! style="background: #F5F5F5;" |M0
 
|-
 
! style="background: #DCDCDC;" |
! style="background: #F5F5F5;" |T1
! style="background: #F5F5F5;" |N1b
! style="background: #F5F5F5;" |M0
 
|-
 
! style="background: #DCDCDC;" |
! style="background: #F5F5F5;" |T2
! style="background: #F5F5F5;" |N1b
! style="background: #F5F5F5;" |M0
 
|-
 
! style="background: #DCDCDC;" |
! style="background: #F5F5F5;" |T3
! style="background: #F5F5F5;" |T3
! style="background: #F5F5F5;" |N1b
! style="background: #F5F5F5;" |N1
! style="background: #F5F5F5;" |M0
! style="background: #F5F5F5;" |M0
|-
|-
 
!
! style="background: #DCDCDC;" |
!T4
! style="background: #F5F5F5;" |T4a
!N0
! style="background: #F5F5F5;" |N1b
!M0
! style="background: #F5F5F5;" |M0
 
|-
|-
 
!
! style="background: #DCDCDC;" |IVB
!T4
! style="background: #F5F5F5;" |T4b
!N1
! style="background: #F5F5F5;" |Any N
!M0
! style="background: #F5F5F5;" |M0
 
|-
|-
 
!
! style="background: #DCDCDC;" |Stage IVC
!Any T
! style="background: #F5F5F5;" |Any T
!Any N
! style="background: #F5F5F5;" |Any N  
!M1
! style="background: #F5F5F5;" |M1
|}
|}


Revision as of 13:57, 18 September 2017

Adrenocortical carcinoma Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Adrenocortical carcinoma from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Staging

History and Symptoms

Physical Examination

Laboratory Findings

X Ray

MRI

CT

Ultrasound

Other Imaging Studies

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Radiation Therapy

Primary prevention

Secondary prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Study

Case #1

Adrenocortical carcinoma staging On the Web

Most recent articles

cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Adrenocortical carcinoma staging

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Adrenocortical carcinoma staging

CDC on Adrenocortical carcinoma staging

Adrenocortical carcinoma staging in the news

Blogs on Adrenocortical carcinoma staging

Hospitals Treating Adrenocortical carcinoma

Risk calculators and risk factors for Adrenocortical carcinoma staging

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief: Ahmad Al Maradni, M.D. [2]

Overview

According to the TNM staging system, there are four stages of adrenocortical cancer based on the tumor size, lymph nodes, and distant metastasis. Each stage is assigned a number and letter that designates the number of lymph nodes involved and presence/absence of distant metastasis.

Staging of adrenocortical carcinoma

The AJCC has designated staging by TNM to define adrenocortical carcinoma[1]

Staging according to TNM staging system

Stage T N M
I T1 N0 M0
II T2 N0 M0
III T1 N1 M0
T2 N1 M0
T3 N0 M0
IV T3 N1 M0
T4 N0 M0
T4 N1 M0
Any T Any N M1

Tumor size (T)

TX Primary tumor cannot be assessed
T0 No evidence of primary tumor
T1 Tumor ≤5 cm in greatest dimension, no extra-adrenal invasion
T2 Tumor >5 cm, no extra-adrenal invasion
T3 Tumor of any size with local invasion, but not invading adjacent organs
T4 Tumor of any size with invasion of adjacent organs

Lymph nodes (N)

NX Regional lymph nodes cannot be assessed
N0 No regional lymph node metastasis
N1 Metastases in regional lymph node(s)

Metastasis (M)

M0 No distant metastasis
M1 Distant metastasis

Staging


Thyroid TNM staging
Stage Description
TX Primary tumor cannot be assessed
T0 No evidence of primary tumor
T1 Tumor ≤5 cm in greatest dimension limited to the adrenals
T2 Tumor >5 cm in greatest dimension, limited to the adrenals
T3 Tumor >4 cm in greatest dimension limited to the thyroid or any tumor with minimal extrathyroid extension (e.g., extension to sternothyroid muscle or perithyroid soft tissues)
T4 Moderately advanced disease
Tumor of any size extending beyond the thyroid capsule to invade subcutaneous soft tissues, larynx, trachea, esophagus, or recurrent laryngeal nerve


Regional Lymph Nodes (N)
Stage Description
NX Regional lymph node cannot be assessed
N0 No regional lymph node metastasis
N1 Regional lymph node metastasis
Distant Metastasis (M)
Stage Description
M0 No distant metastasis
M1 Distant metastasis
Anatomic Stage/Prognostic Groups
Stage T N M
Papillary thyroid carcinoma
YOUNGER THAN 45 YEARS
I T1 N0 M0
II T2 N0 M0
III T1 N1 M0
T2 N1 M0
T3 N0 M0
IV T3 N1 M0
T4 N0 M0
T4 N1 M0
Any T Any N M1

References

  1. ↑ Adrenal. In: Edge SB, Byrd DR, Compton CC, et al., eds.: AJCC Cancer Staging Manual. 7th ed. New York, NY: Springer, 2010, pp 516-7

Template:WH Template:WS

Retrieved from "https://www.wikidoc.org/index.php?title=Adrenocortical_carcinoma_staging&oldid=1353173"